Evidence map›Paper›PMID 42032485›Full record

ArticleBMC cancer2026

SPINAL: study protocol for a multicenter non-inferiority trial evaluating reduce vertebral irradiation volumes in palliative radiotherapy for spinal bone metastases on analgesic efficacy.

Jean-Christophe Faivre, Aurélien Lambert, Marie Bruand, Adrian Francais, Stéphane Supiot, Sébastien Thureau, Vincent Bourbonne, Florine Tomaszewski, Claire Charra-Brunaud, Jean-François Py and 14 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Jean-Christophe FaivreRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France. jc.faivre@nancy.unicancer.fr.
Aurélien LambertMedical Oncology Department, UMR 1319 INSPIIRE, Inserm, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, 54519, France.
Marie BruandRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Adrian FrancaisBiostatsitics and datamanagement, Delta Consultants, Eybens, 33820, France.
Stéphane SupiotDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest - site René Gauducheau, Saint Herblain, 44 800, France.
Sébastien ThureauDepartment of Radiation Oncology, Centre Henri Becquerel, Rouen, 76000, France.
Vincent BourbonneRadiation Oncology Department, CHU de Brest, 2 avenue Foch, Brest, 29200, France.
Florine TomaszewskiDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest - site René Gauducheau, Saint Herblain, 44 800, France.
Claire Charra-BrunaudRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Jean-François PyRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Anaïs StefaniRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Maria JolnerovskiRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Nicolas DemogeotRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Mathilde CueninRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Sophie RenardRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Selima SellamiRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Ida TrampettiRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Valérie Bernier-ChastagnerRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Juliette JacquesRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Emma AgnouxRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Richard Au AppavouMedical physic department, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, 54519, France.
William GehinRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Nicolas MartzRadiation Department, Institut de Cancérologie de Lorraine, Vandoeuvre- Lès-Nancy, 54519, France.
Nour MammariDepartement of Clinical Research, Institut de Cancérologie de Lorraine, Université de Lorraine, Vandoeuvre-lès-Nancy, 54 511, France.

Funding

The National Ligue against the cancer AAPDOULEUR 2025.LCC/JeF
6 · The paper itself

Abstract

backgroundPalliative analgesic radiotherapy is commonly used to alleviate pain in patients with bone metastases. Traditionally, this approach involved irradiating the vertebrae above and below the painful lesion. The 2D/3D radiotherapy technique, characterized by a physical penumbra that could extend up to 50% of the vertebral height, often resulted in underdosing of the target volume and potentially reduced analgesic effectiveness. However, the advent of CT and MRI imaging, along with image-guided radiation therapy, has largely replaced these practices by enabling precise delineation of target volumes. With modern radiotherapy equipment, the physical penumbra has become negligible, reducing the need for large treatment margins and minimizing irradiation of healthy tissues and associated side effects. The primary objective of this study is to assess the impact of reducing the irradiated volume in palliative treatment of metastatic bone disease on analgesic effectiveness at day 30. As a secondary objective, the study aims to evaluate the effectiveness of telemonitoring in identifying patients who may benefit from patient-reported outcomes (PROs) and require additional care, such as further analgesic radiotherapy.

methodsThis clinical trial is designed as a multicenter, randomized, prospective non-inferiority study with two parallel arms: a standard arm involving spinal irradiation including adjacent vertebrae, and an experimental arm involving spinal irradiation with sparing of adjacent vertebrae.

conclusionsIf successful, this approach could lead to significant changes in current palliative radiotherapy practices by reducing the risk of treatment-related toxicity and improving patients’ quality of life.

Indexed as

Cancer PainPalliative CareSpinal NeoplasmsAnalgesicsEquivalence Trials as TopicFemaleHumansMaleMulticenter Studies as TopicProspective StudiesRadiotherapy, Image-GuidedRandomized Controlled Trials as TopicSpineAnalgesicsAnalgesic efficacyPalliative radiotherapySpinal bone metastasesTelemedicine

Identifiers

PMID42032485
PMCPMC13245005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.